Table 1. CR and Early Mortality in APL... | American Society of Hematology

Table 1.

CR and Early Mortality in APL Patients Treated With ATRA

Reference	No. Patients		% CR		Deaths in Induction (%)
	No. Patients		% CR		Total		Hemorrhagic		Thrombotic
	ATRA	C	ATRA	C	ATRA	C	ATRA	C	ATRA	C
Nonrandomized Trials (with historical controls)
86	26	29	96	76	4	NR	4	NR	NR	NR
87	51	80	86	NR	17	21	NR	NR	NR	NR
88	109	62	89	71^-150	8	20^-150	NR	NR	NR	NR
89	43	57	77	68	19	30	12	18	NR	NR
85	434	244	92	71^-150	2	8^-150	1	6^-150	0.2	0
Randomized Clinical Trials
81	54	47	91	81	9	8	5.5	6.4	0	0
93	172	174	72	69	11	14	5.8	6.9	1.7	0

Reference	No. Patients		% CR		Deaths in Induction (%)
	No. Patients		% CR		Total		Hemorrhagic		Thrombotic
	ATRA	C	ATRA	C	ATRA	C	ATRA	C	ATRA	C
Nonrandomized Trials (with historical controls)
86	26	29	96	76	4	NR	4	NR	NR	NR
87	51	80	86	NR	17	21	NR	NR	NR	NR
88	109	62	89	71^-150	8	20^-150	NR	NR	NR	NR
89	43	57	77	68	19	30	12	18	NR	NR
85	434	244	92	71^-150	2	8^-150	1	6^-150	0.2	0
Randomized Clinical Trials
81	54	47	91	81	9	8	5.5	6.4	0	0
93	172	174	72	69	11	14	5.8	6.9	1.7	0

Abbreviations: C, controls; GIMEMA, Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (refs 85 and 90); NR, not reported.

P < .05.